Pipeline

Mesentech is advancing MES—1007 through preclinical safety evaluation in preparation to file an investigational new drug application to the US Food and Drug Administration.

Our IP consists of New Chemical Entities (NCEs) and have composition of matter patents that also cover the most direct synthesis methods. These patents expire 2033 to 2038. The clinical candidate has a composition of matter patent that expires 2038.